Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms - Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms

Division of Urology, Kobe University Graduate School of Medicine0 个研究点目标入组 200 人开始时间: 2012年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) patients are having the disease other than a benign prostatic hyperplasia (prostate cancer, bladder tumors, bladder stones, prostatitis, bladder neck sclerosis, patients, etc.) 2) Patients have received TUR-P, balloon dilation, urethral stent, hyperthermia, or radiation therapy to the pelvis, within 6 months of the start of the study 3) Self-catheterization 4) Patients with urinary tract infection 5) Patients with concomitant disease and other nervous system diseases, and it suspected to be neurogenic bladder 6) Patients with concomitant severe ischemic heart disease, cerebrovascular disease, liver dysfunction, renal dysfunction. 7) Patients with hypotension 8) Patients are having hypersensitivity to silodosin, naftopidil or taking vardenafil hydrochloride 9) Patients have treated with hormonal drug within 6 months 10) Patients treated with drugs other than tamsulosin is considered effective on urinary symptoms within a week 11) Patients was deemed by the physician as inappropriate to attend

发起方

Division of Urology, Kobe University Graduate School of Medicine